

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 29, 2020 (the “**Prospectus**”) of Ocumension Therapeutics (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to sell, acquire, purchase or subscribe for any securities.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or elsewhere. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws of the United States and may not be offered or sold in the United States absent registration under the U.S. Securities Act or except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. There will be no public offering of securities of the Company in the United States.



Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

**FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,
STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option described in the Prospectus has been fully exercised by the Representatives of International Underwriters on behalf of the International Underwriters on August 2, 2020, in respect of an aggregate of 15,889,500 Shares (the “**Over-allotment Shares**”), representing 15% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return of the borrowed Shares under the Stock Borrowing Agreement which were used to cover over-allocations in the International Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on August 2, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Further information on the stabilizing actions undertaken by the Stabilization Manager during the stabilization period is set out in this announcement.

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that on August 2, 2020 the Over-allotment Option described in the Prospectus has been fully exercised by the Representatives of International Underwriters, on behalf of the International Underwriters, in respect of an aggregate of 15,889,500 Shares, representing 15% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), to cover over-allocations in the International Offering.

The Over-allotment Shares will be allotted and issued by the Company at HK\$14.66 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering. The Over-allotment Shares will be used to facilitate the return of 15,889,500 borrowed Shares to 6 Dimensions Capital, L.P., which were used to cover over-allocations of Shares in the International Offering.

APPROVAL OF LISTING

Approval for the listing of, and permission to deal in, the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of, and dealing in, the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on August 5, 2020.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE FULL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after the completion of the full exercise of the Over-allotment Option is as follows:

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	<i>Number of Shares</i>	<i>Approximate percentage of the Company's issued share capital</i>	<i>Number of Shares</i>	<i>Approximate percentage of the Company's issued share capital</i>
6 Dimensions Capital, L.P.	123,975,000 ⁽¹⁾	21.55%	123,975,000	20.97%
6 Dimensions Affiliates Fund, L.P.	6,525,000	1.13%	6,525,000	1.10%
Suzhou Frontline BioVentures Venture Capital Fund II L.P.	91,350,000	15.88%	91,350,000	15.45%
Suzhou 6 Dimensions Venture Capital Partnership L.P.	39,150,000	6.81%	39,150,000	6.62%
Summer Iris Limited	78,214,230	13.60%	78,214,230	13.23%
Boyu Capital Opportunities Master Fund	2,642,500	0.46%	2,642,500	0.45%
TLS Beta Pte. Ltd.	54,169,400 ⁽²⁾	9.42%	54,169,400 ⁽²⁾	9.16%
Mr. Ye LIU, CEO and executive Director of the Company	5,836,730	1.01%	5,836,730	0.99%

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	Number of Shares	Approximate percentage of the Company's issued share capital	Number of Shares	Approximate percentage of the Company's issued share capital
Coral Incentivization Limited	24,000,000	4.17%	24,000,000	4.06%
Other pre-IPO Shareholders ⁽³⁾	51,385,760	8.93% ⁽⁴⁾	51,385,760	8.69% ⁽⁴⁾
Other public Shareholders	98,002,000	17.04% ⁽⁴⁾	113,891,500	19.27% ⁽⁴⁾
Total	575,250,620	100%	591,140,120	100%

Notes:

- (1) Inclusive of the 15,889,500 Shares lent to Morgan Stanley & Co. International plc under the Stock Borrowing Agreement.
- (2) Includes 48,883,900 Shares held by TLS Beta Pte. Ltd. as an existing Shareholder of the Company and 5,285,500 Shares subscribed by it as a cornerstone investor.
- (3) These refer to all other Pre-IPO Investors. For details, please see the section headed “History, Restructuring and Corporate Structure – Capitalization of The Company”.
- (4) Any discrepancies in the table between the totals and sums of amounts listed therein are due to rounding.

USE OF PROCEEDS

The Company will receive additional net proceeds of approximately HK\$222.44 million from the issue of the Over-allotment Shares, after deducting the incentive fee, commission and other offering expenses payable by the Company in relation to the exercise of the Over-allotment Option. The Company intends to utilize the additional net proceeds on a *pro rata* basis for the purposes as set out in the section headed “Future Plans and Use of Proceeds – Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on August 2, 2020, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by Morgan Stanley Asia Limited, as Stabilization Manager, or any person acting for it during the stabilization period were:

- (1) over-allocations of an aggregate of 15,889,500 Shares in the International Offering, representing 15% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option);
- (2) the borrowing of 15,889,500 Shares by Morgan Stanley & Co. International plc, as an affiliate of the Stabilization Manager, from 6 Dimensions Capital, L.P., pursuant to the Stock Borrowing Agreement to cover the over-allocations in the International Offering. Such Shares will be returned and redelivered to 6 Dimensions Capital, L.P. in accordance with the terms of the Stock Borrowing Agreement; and

- (3) the full exercise of the Over-allotment Option by the Representatives of International Underwriters, on behalf of the International Underwriters on August 2, 2020, in respect of an aggregate of 15,889,500 Shares, representing 15% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), at the Offer Price, to facilitate the return to 6 Dimensions Capital, L.P. of all of the borrowed Shares which were used to cover the over-allocations in the International Offering.

There had been no purchase or sale of any Shares on the market for the purpose of price stabilization by the Stabilization Manager during the stabilization period.

PUBLIC FLOAT

Immediately after the completion of the Global Offering and after the full exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules.

By order of the Board
Ocumension Therapeutics
Lian Yong CHEN
Chairman

Hong Kong, August 2, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Lian Yong CHEN as Chairman and executive Director, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive Directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE and Mr. Yiran HUANG as independent non-executive Directors.